People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles ...

Autoimmune generalized myasthenia gravis is a disease that manifests with fluctuating muscle weakness. Inebilizumab is a monoclonal antibody that depletes CD19+ B cells, which are central to ...

As a result, the muscles become weak when a person performs repeated physical movements. The disease is neither contagious nor inherited but it is often misunderstood as a psychological issue or ...

The body's immune system mistakenly produces "autoantibodies," or antibodies that attack its own tissues and proteins. In the case of myasthenia gravis, the body produces autoantibodies that ...

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

gMG is different from ocular myasthenia gravis, which only affects the eye muscles. “Anti-acetylcholine receptor (AChR) antibody-positive” means your immune system makes antibodies that block ...

Treatment with inebilizumab is significantly effective and safe for patients with AChR+ or MuSK+ generalized myasthenia ...

YANTAI, China I April 8, 2025 I On April 8, 2025 (UTC-7), impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and ...